| Source: |
| Type: |
| Power to enhance an anti cancer effect |
| Renal cell carcinoma (RCC) is one of the most common malignant tumors of the urinary system, accounting for 80–90% of kidney neoplasms. The activation of the mTOR pathway has been found in RCC and is correlated with high grade and poor prognostic patient features (41,42). |
| 1374- | BBR, | PDT, | Berberine associated photodynamic therapy promotes autophagy and apoptosis via ROS generation in renal carcinoma cells |
| - | in-vitro, | RCC, | 786-O | - | in-vitro, | RCC, | HK-2 |
| 5740- | Buty, | A Review of Nutritional Regulation of Intestinal Butyrate Synthesis: Interactions Between Dietary Polysaccharides and Proteins |
| - | Review, | RCC, | NA |
| 6018- | CGA, | Chlorogenic acid: a review on its mechanisms of anti-inflammation, disease treatment, and related delivery systems |
| - | Review, | Var, | NA | - | Review, | RCC, | NA |
| 2383- | MET, | Activation of AMPK by metformin promotes renal cancer cell proliferation under glucose deprivation through its interaction with PKM2 |
| - | in-vitro, | RCC, | A498 |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
| 3121- | VitC, | immuno, | Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma |
| - | in-vivo, | RCC, | A498 | - | in-vitro, | RCC, | 786-O |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:24 Cells:% prod#:% Target#:961 State#:% Dir#:2
wNotes=0 sortOrder:rid,rpid